BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17085660)

  • 1. Classification of breast cancer using genetic algorithms and tissue microarrays.
    Dolled-Filhart M; Rydén L; Cregger M; Jirström K; Harigopal M; Camp RL; Rimm DL
    Clin Cancer Res; 2006 Nov; 12(21):6459-68. PubMed ID: 17085660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Predictive and prognostic markers of breast cancer. Molecular biological analysis of fixed tumor tissue].
    Petry C; Gehrmann M; von Törne C; Weber K; Stropp U; Hennig G
    Pathologe; 2008 Nov; 29 Suppl 2():181-3. PubMed ID: 18843491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
    Zerkowski MP; Camp RL; Burtness BA; Rimm DL; Chung GG
    Cancer Invest; 2007 Feb; 25(1):19-26. PubMed ID: 17364553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome.
    Dolled-Filhart M; McCabe A; Giltnane J; Cregger M; Camp RL; Rimm DL
    Cancer Res; 2006 May; 66(10):5487-94. PubMed ID: 16707478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in projecting clustering results across gene expression-profiling datasets.
    Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
    J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.
    Crabb SJ; Bajdik CD; Leung S; Speers CH; Kennecke H; Huntsman DG; Gelmon KA
    Breast Cancer Res; 2008; 10(1):R6. PubMed ID: 18194560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commercialized multigene predictors of clinical outcome for breast cancer.
    Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
    Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.
    Harigopal M; Heymann J; Ghosh S; Anagnostou V; Camp RL; Rimm DL
    Breast Cancer Res Treat; 2009 May; 115(1):77-85. PubMed ID: 18521745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model.
    Altstock RT; Stein GY; Resau JH; Tsarfaty I
    Cytometry; 2000 Nov; 41(3):155-65. PubMed ID: 11042611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.
    Malinowski DP
    Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue.
    Hartmann E; Fernàndez V; Moreno V; Valls J; Hernández L; Bosch F; Abrisqueta P; Klapper W; Dreyling M; Hoster E; Müller-Hermelink HK; Ott G; Rosenwald A; Campo E
    J Clin Oncol; 2008 Oct; 26(30):4966-72. PubMed ID: 18606985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
    Voduc D; Nielsen TO; Cheang MC; Foulkes WD
    Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical validation of a customized multiple signature microarray for breast cancer.
    Tan BK; Tan LK; Yu K; Tan PH; Lee M; Sii LH; Wong CY; Ho GH; Yeo AW; Chow PK; Koong HN; Yong WS; Lim DT; Ooi LL; Soo KC; Tan P
    Clin Cancer Res; 2008 Jan; 14(2):461-9. PubMed ID: 18223220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High HSP90 expression is associated with decreased survival in breast cancer.
    Pick E; Kluger Y; Giltnane JM; Moeder C; Camp RL; Rimm DL; Kluger HM
    Cancer Res; 2007 Apr; 67(7):2932-7. PubMed ID: 17409397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays.
    Cheng H; Dodge J; Mehl E; Liu S; Poulin N; van de Rijn M; Nielsen TO
    Hum Pathol; 2009 Sep; 40(9):1244-51. PubMed ID: 19368956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.